About Cesca Therapeutics
Cesca Therapeutics is a company based in Rancho Cordova (United States) founded in 1986. Cesca Therapeutics has completed 1 acquisition, including SynGen. Cesca Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Rancho Cordova, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Totipotentsc Scientific Product Private Limited
- Date of Incorporation 28 Mar, 2008
- Jurisdiction Gurugram, Haryana, India
-
Annual Revenue
$336.78 K (USD)-20.7as on Mar 31, 2017
-
Net Profit
-$80.18 K (USD)8.35as on Mar 31, 2017
-
EBITDA
-$103.03 K (USD)-13.62as on Mar 31, 2017
-
Latest Funding Round
$800 K (USD), Post-IPO
Feb 13, 2019
- Investors
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cesca Therapeutics
Unlock access to complete
Leadership Team
3 people
Operations Team
1 people
Sr. Team
1 people
Software Development Team
1 people
Unlock access to complete
Funding Insights of Cesca Therapeutics
Investors in Cesca Therapeutics
Cesca Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Boyalife Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Cesca Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cesca Therapeutics
Cesca Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SynGen.
Investment portfolio details for Cesca Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Develops cell separation tools and accessories
|
Locked | Locked | 2009 | Locked |
Complete acquisition details for Cesca Therapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cesca Therapeutics
Detailed financials for Cesca Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cesca Therapeutics Comparisons
Peer comparison for Cesca Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cesca Therapeutics
Cesca Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of Cesca Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cesca Therapeutics
Complete news archive for Cesca Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cesca Therapeutics
Cesca Therapeutics was founded in 1986 and raised its 1st funding round 16 years after it was founded.
Cesca Therapeutics is headquartered in Rancho Cordova, United States. It is registered at Rancho Cordova, California, United States.
Annual revenue of Cesca Therapeutics is $336.78K as on Mar 31, 2017.
Cesca Therapeutics is engaged in the development of cell-based therapeutics as regenerative medicine. It was formed by the merger of Thermogenesis which supplies a supplier of enabling technologies for the processing and storage of stem cells and TotipotentRx which develops cell-based therapies. Its lead therapeutic technology platform SurgWerks harvests, selects and delivers a dose of autologous bone marrow derived or peripheral blood-derived cells and proteins. The technology is currently in clinical trials as a potential treatment for acute myocardial infarction, critical limb ischemia, and orthopedic injuries. It also manufactures devices created specifically for regenerative medicine. Besides, it also provides cell manufacturing and banking services.
Cesca Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Cesca Therapeutics has made 1 acquisition, including SynGen.
Cesca Therapeutics has 1 investor. Key investors include Boyalife Group.